摘要临床研究奠定了表皮生长因子受体酪氨酸激酶抑制剂(EGFR－TKI)辅助靶向治疗的临床应用地位。与化疗比较，靶向药高效低不良反应的特点为患者增加了生存获益。埃克替尼是中国第1个拥有自主知识产权、也是全球第3个上市的EGFR－TKI。2021年6月埃克替尼获得批准用于Ⅱ~ⅢA期EGFR敏感突变非小细胞肺癌术后辅助治疗适应证，同年获得中国临床肿瘤学会指南Ⅰ级推荐，成为全球第1个获批术后辅助医保适应证并有指南推荐的第一代EGFR－TKI。为了总结目前埃克替尼及其他EGFR－TKIs辅助治疗非小细胞肺癌的用药经验，进一步规范、指导埃克替尼的临床应用，由中国医疗保健国际交流促进会、广东省胸部疾病学会组织专家编写了埃克替尼术后辅助治疗非小细胞肺癌的专家共识，期待能为临床医师提供术后靶向用药的循证医学证据。

abstractsClinical studies have established the clinical application of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) adjuvant targeted therapy. Compared with chemotherapy, the high efficiency and low toxicity of targeted therapy increases the survival benefit of patients. Icotinib was the first EGFR-TKI with independent intellectual property rights in China and the third EGFR-TKI to be marketed in the world. In order to summarize the experience of icotinib and other EGFR-TKIs in the adjuvant treatment of non-small cell lung cancer and further standardize and guide the clinical application of icotinib, experts from the China International Exchange and Promotive Association for Medical and Health Care and the Guangdong Association of Thoracic Diseases have organized an expert consensus on the adjuvant treatment of non-small cell lung cancer with icotinib, which is expected to provide clinicians with evidence-based medical evidences for postoperative targeted drug using.